Incyte (INCY) CMO granted 44,124 performance-based shares in Form 4/A
Rhea-AI Filing Summary
Stein Steven H reported acquisition or exercise transactions in this Form 4 filing.
Incyte Corp chief medical officer Steven H. Stein reported an amended insider transaction showing he earned 44,124 shares of common stock tied to performance shares. The compensation committee determined on May 6, 2026 that specified development, revenue and market-based goals had been achieved.
The earned shares will vest on the third anniversary of the July 14, 2023 grant date, as long as he continues serving the company. Including this certification, Stein now has 78,327 shares of common stock issuable from previously reported restricted stock units and earned performance shares that have not yet vested.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 44,124 shares
Net Buy
1 txn
Insider
Stein Steven H
Role
CMO & Head of Late-Stage Dev.
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 44,124 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 78,327 shares (Direct)
Footnotes (3)
- F1. Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on May 6, 2026. The earned shares will vest on the third anniversary of the July 14, 2023 grant date, subject to the Reporting Person's continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuer's Compensation Committee in January 2023 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three-year performance period ranges from 0% to 150% of the number of performance shares awarded.
- F2. This Form 4/A amends the original Form 4, filed on April 17, 2026, to reflect the Compensation Committee's determination on May 6, 2026 relating to the achievement of the performance criteria, which superseded the Compensation Committee's initial determination on April 15, 2026.
- F3. Including this certification of performance shares, this includes an aggregate of 78,327 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.
Key Figures
Performance shares earned: 44,124 shares
Post-transaction unvested equity: 78,327 shares
Grant date reference: July 14, 2023
+2 more
5 metrics
Performance shares earned
44,124 shares
Common stock underlying performance shares earned May 6, 2026
Post-transaction unvested equity
78,327 shares
Common stock issuable from RSUs and earned performance shares not yet vested
Grant date reference
July 14, 2023
Original grant date; earned shares vest on third anniversary
Award price
$0.0000 per share
Indicates compensation grant, not open-market purchase
Performance payout range
0% to 150%
Range of common shares deliverable over three-year performance period
Key Terms
performance shares, restricted stock units, Performance Share Award Agreement, relative total shareholder returns, +1 more
5 terms
restricted stock units financial
"includes an aggregate of 78,327 shares of common stock issuable pursuant to previously reported restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Nasdaq Biotechnology Index financial
"relative total shareholder returns compared to the Nasdaq Biotechnology Index"
A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Incyte (INCY) report for Steven H. Stein?
Incyte reported that CMO Steven H. Stein earned 44,124 shares of common stock from performance shares. These were awarded at no cost after the compensation committee confirmed performance goals were met on May 6, 2026, and remain subject to future vesting.
Why was this Form 4/A amendment filed for Incyte (INCY)?
The Form 4/A was filed to update a prior April 17, 2026 report after the compensation committee’s May 6, 2026 determination on performance criteria. That new decision superseded its initial April 15, 2026 assessment of how many performance-based shares were earned.
Was Steven H. Stein’s Incyte (INCY) award an open-market stock purchase?
No, the 44,124 Incyte shares were earned as a performance-based equity award with a zero-dollar price per share. This reflects compensation determined by the board’s compensation committee, rather than Stein buying shares on the open market.